dasatinib

Consistent with these subtype-specific features, CS1 tumors exhibited distinct sensitivities to dasatinib, lapatinib, paclitaxel, and cisplatin, indicating immune-state-associated therapeutic vulnerabilities. Together, these findings suggest a RUNX1-associated immunosuppressive tumor ecology in UVM and provide a conceptual framework for immune-state-guided therapeutic strategies.

P1, N=20, Active, not recruiting, OHSU Knight Cancer Institute | Trial completion date: Dec 2026 --> Dec 2027 | Trial primary completion date: Dec 2026 --> Dec 2027 | Recruiting --> Active, not recruiting

P2, N=23, Completed, Washington University School of Medicine | Active, not recruiting --> Completed

PCS outperformed DEGs in drug repurposing predictions and exhibited higher disease specificity. The availability of tumor-normal paired samples with RFS was limited. Our method lacked comparisons with alternative approaches. PCS exhibited limited predictive utility in certain tumor types, suggesting its potential unsuitability for all solid tumors. PCS had a notable flaw, as positive scores also enriched some treatment drugs.

P2, N=17, Active, not recruiting, Baylor College of Medicine | N=100 --> 17 | Recruiting --> Active, not recruiting

BCR::ABL1 e6a3 demonstrated enhanced sensitivity to active-state selective inhibitors dasatinib and bosutinib, whereas BCR::ABL1 e6a3/T315I remained resistant. These data show that treatment with asciminib and ponatinib can select for mutations with notably elevated enzymatic activity, effectively targeted by an axitinib-based triple combination. These data highlight the remarkable mutability of the BCR::ABL1 kinase, including through novel isoforms and provides a strong rationale for the clinical assessment of a triple inhibitor combination as a strategy to overcome resistance to dual ponatinib and asciminib therapy.

P2, N=406, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Mar 2026 --> Mar 2027

Drug sensitivity prediction suggested low-risk patients were more responsive to temozolomide and bortezomib, whereas high-risk patients were more sensitive to dasatinib and ruxolitinib. These findings suggest host-T. gondii interactions and a potential biomarker for patient stratification and personalized therapy.

TKI-associated bone marrow aplasia has been reported with agents such as imatinib, dasatinib, and nilotinib. This case supports the potential role of ponatinib as an effective salvage option following severe TKI-related marrow toxicity, particularly in patients who are not candidates for allogeneic transplantation. Further clinical experience and larger studies are needed to better define optimal management strategies for this rare but serious complication.

BIOMEDE was a randomized phase 2 trial comparing the efficacy in terms of overall survival (OS) (primary endpoint) of epidermal growth factor receptor (EGFR) inhibitor erlotinib, mTOR inhibitor everolimus and multitargeted tyrosine kinase inhibitor dasatinib in combination with radiotherapy in patients with a biopsy-proven DIPG...A cohort of 66 children with the same inclusion criteria and treated previously with temozolomide-based regimen was used to compare outcome...With comprehensive tumor profiling, BIOMEDE validated prognostic biomarkers as well as informative theranostic biomarkers for future trials. ClinicalTrials.gov: NCT02233049 .

Following a multidisciplinary tumor board discussion, the patient underwent reduced-intensity induction with mini-CVD (cyclophosphamide, vincristine, and dexamethasone) combined with dasatinib and central nervous system prophylaxis. The patient experienced clinical and hematologic improvement and was discharged on continuous tyrosine kinase inhibitor therapy with close monitoring. This case highlights the diagnostic workup, multidisciplinary treatment planning, and early therapeutic response in an elderly patient with Ph+ B-ALL while comparing these findings with the current literature.